The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

Biosimilars revolutionize health care access in Latin America, offering cost savings and improved treatment availability for ...

A new study confirms that biosimilar ranibizumab matches innovator Lucentis in treating myopic choroidal neovascular membrane ...

Researchers report that biosimilar use was not influenced by disease type but correlated with treatment sequence, shorter ...

Biosimilars and generics drive significant health care savings, yet a concerning lack of biosimilar development for biologics set to lose exclusivity in the next 10 years threatens future access and ...

New research confirms the romiplostim biosimilar GP40141 offers comparable efficacy and safety for treating immune thrombocytopenia, enhancing treatment accessibility. The romiplostim biosimilar ...

New research highlights the efficacy and high patient satisfaction of adalimumab biosimilars in treating inflammatory diseases. In response to the need for more real-world evidence on adalimumab ...

Denosumab biosimilars Wyost and Jubbonti launch in the US, enhancing access to affordable treatments for osteoporosis and cancer-related skeletal events. The US pharmaceutical market has witnessed the ...

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...

To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the ...

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost ...

The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.